4BIO Capital and Arkin Bio Ventures lead first close joined by Takeda Ventures and existing investors NEW YORK, March 25, 2020-- Redpin Therapeutics, Inc., a pioneering chemogenetics company developing uniquely controllable gene therapies to address intractable diseases of the nervous system, today announced it has secured $15.5 million in the initial closing of its Series A financing round.